CN112601550B - 抗-乙型淀粉样蛋白抗体及其用途 - Google Patents

抗-乙型淀粉样蛋白抗体及其用途 Download PDF

Info

Publication number
CN112601550B
CN112601550B CN201980036565.6A CN201980036565A CN112601550B CN 112601550 B CN112601550 B CN 112601550B CN 201980036565 A CN201980036565 A CN 201980036565A CN 112601550 B CN112601550 B CN 112601550B
Authority
CN
China
Prior art keywords
antibody
seq
sequence
abeta
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980036565.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN112601550A (zh
Inventor
谢奉勋
徐祖安
石全
沈三泰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Health Research Institutes
Original Assignee
National Health Research Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Health Research Institutes filed Critical National Health Research Institutes
Publication of CN112601550A publication Critical patent/CN112601550A/zh
Application granted granted Critical
Publication of CN112601550B publication Critical patent/CN112601550B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201980036565.6A 2018-05-30 2019-05-29 抗-乙型淀粉样蛋白抗体及其用途 Active CN112601550B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678080P 2018-05-30 2018-05-30
US62/678,080 2018-05-30
PCT/US2019/034259 WO2019231957A1 (en) 2018-05-30 2019-05-29 Anti-abeta antibodies and uses thereof

Publications (2)

Publication Number Publication Date
CN112601550A CN112601550A (zh) 2021-04-02
CN112601550B true CN112601550B (zh) 2023-12-08

Family

ID=68694402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980036565.6A Active CN112601550B (zh) 2018-05-30 2019-05-29 抗-乙型淀粉样蛋白抗体及其用途

Country Status (8)

Country Link
US (1) US11084873B2 (https=)
EP (1) EP3801618A4 (https=)
JP (1) JP7210612B2 (https=)
KR (1) KR102523019B1 (https=)
CN (1) CN112601550B (https=)
CA (1) CA3100896C (https=)
TW (1) TWI721440B (https=)
WO (1) WO2019231957A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101325972A (zh) * 2005-12-12 2008-12-17 Ac免疫有限公司 具有治疗性质的Aβ1-42特异性单克隆抗体
CN102006887A (zh) * 2007-11-16 2011-04-06 洛克菲勒大学 初原纤维形式β-淀粉样蛋白的特异性抗体
WO2014151747A1 (en) * 2013-03-15 2014-09-25 Ramot At Tel Aviv University Ltd. Methods and compositions with immune therapy for treatment of dementia
WO2015161311A2 (en) * 2014-04-18 2015-10-22 The Research Foundation For The State University Of New York Humanized anti-tf-antigen antibodies
WO2017079831A1 (en) * 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201404801YA (en) * 2005-12-12 2014-09-26 Ac Immune Sa Monoclonal antibody
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
WO2009033743A1 (en) * 2007-09-13 2009-03-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
WO2009063970A1 (ja) * 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. 抗gpr49抗体を用いる癌の診断および治療
ES2624835T3 (es) * 2009-08-06 2017-07-17 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a los oligómeros A beta y uso de los mismos
CN105979962A (zh) 2012-12-07 2016-09-28 比奥根国际神经科学公司 使用抗Aβ抗体减少脑淀粉样蛋白斑块的方法
DK3430397T3 (da) * 2016-03-14 2022-05-02 Biogen Int Neuroscience Gmbh Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101325972A (zh) * 2005-12-12 2008-12-17 Ac免疫有限公司 具有治疗性质的Aβ1-42特异性单克隆抗体
CN102006887A (zh) * 2007-11-16 2011-04-06 洛克菲勒大学 初原纤维形式β-淀粉样蛋白的特异性抗体
WO2014151747A1 (en) * 2013-03-15 2014-09-25 Ramot At Tel Aviv University Ltd. Methods and compositions with immune therapy for treatment of dementia
WO2015161311A2 (en) * 2014-04-18 2015-10-22 The Research Foundation For The State University Of New York Humanized anti-tf-antigen antibodies
WO2017079831A1 (en) * 2015-11-09 2017-05-18 The University Of British Columbia N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
抗Aβ42单链抗体对阿尔茨海默病小鼠脑中淀粉样沉积的改善作用;刘秦;方勇涛;陈源;陈晓云;;中国老年学杂志(第13期);全文 *
靶向β-淀粉样蛋白的阿尔茨海默病免疫治疗研究进展;余云舟;徐青;;国际药学研究杂志(第02期);全文 *

Also Published As

Publication number Publication date
KR102523019B1 (ko) 2023-04-18
AU2019277171A1 (en) 2020-12-03
CN112601550A (zh) 2021-04-02
EP3801618A1 (en) 2021-04-14
TWI721440B (zh) 2021-03-11
JP2021525512A (ja) 2021-09-27
JP7210612B2 (ja) 2023-01-23
CA3100896A1 (en) 2019-12-05
TW202033549A (zh) 2020-09-16
US20190367593A1 (en) 2019-12-05
CA3100896C (en) 2023-08-29
WO2019231957A1 (en) 2019-12-05
KR20210041535A (ko) 2021-04-15
US11084873B2 (en) 2021-08-10
EP3801618A4 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
AU2013302540B2 (en) Methods of treating a tauopathy
US10208111B2 (en) Alpha-synuclein antibodies and uses thereof
RU2644242C2 (ru) Гуманизированное тау-антитело
CA2812865C (en) Phosphospecific antibodies recognising tau
US9216217B2 (en) Oligomer-specific amyloid beta epitope and antibodies
JP7173618B2 (ja) アルファ－シヌクレインに対する抗体およびその用途
KR20100097651A (ko) 베타-아밀로이드 펩티드에 특이적인 신규 항체 및 진단제 또는 진단약으로서의 그 용도
CN112601550B (zh) 抗-乙型淀粉样蛋白抗体及其用途
US12351623B2 (en) Antibody compositions targeting non-phosphorylated alpha-synuclein aggregates
WO2016092865A1 (ja) アミロイドβの２２位及び２３位のターン構造を極めて特異的に認識する抗体
JP2026503664A (ja) 抗ａベータ抗体を用いた神経障害の治療方法
HK40040248A (en) Anti-abeta antibodies and uses thereof
HK40040248B (zh) 抗-乙型淀粉样蛋白抗体及其用途
JP2026504818A (ja) 抗アミロイドβプロトフィブリル／オリゴマー抗体およびその使用
HK40113703A (zh) 神经变性疾病的治疗剂
WO2023077091A1 (en) Anti-amyloid beta antibodies and methods of using the same
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40040248

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant